PP11 Presentation Time: 11:30 AM

Purpose: High dose rate (HDR) brachytherapy as primary therapy (monotherapy) is a standard National Comprehensive Cancer Network (NCCN) endorsed treatment option for patients with localized prostate cancer. Most data to date are limited to single institution experiences. Accordingly, we sought to systematically review rates of biochemical recurrence-free survival (bRFS) and toxicity associated with HDR monotherapy.

Source: Brachytherapy - May 1, 2021 Category: Cancer & Oncology Authors: Eric Anderson, Sungjin Kim, Howard Sandler, Mitchell Kamrava Source Type: research